Luzzi K J, MacDonald I C, Schmidt E E, Kerkvliet N, Morris V L, Chambers A F, Groom A C
Department of Medical Biophysics, University of Western Ontario, London Regional Cancer Centre, Canada.
Am J Pathol. 1998 Sep;153(3):865-73. doi: 10.1016/S0002-9440(10)65628-3.
In cancer metastasis, only a small percentage of cells released from a primary tumor successfully form distant lesions, but it is uncertain at which steps in the process cells are lost. Our goal was to determine what proportions of B16F1 melanoma cells injected intraportally to target mouse liver 1) survive and extravasate, 2) form micrometastases (4 to 16 cells) by day 3, 3) develop into macroscopic tumors by day 13, and 4) remain as solitary dormant cells. Using in vivo videomicroscopy, a novel cell accounting assay, and immunohistochemical markers for proliferation (Ki-67) and apoptosis (TUNEL), we found that 1) 80% of injected cells survived in the liver microcirculation and extravasated by day 3, 2) only a small subset of extravasated cells began to grow, with 1 in 40 forming micrometastases by day 3, 3) only a small subset of micrometastases continued to grow, with 1 in 100 progressing to form macroscopic tumors by day 13 (in fact, most micrometastases disappeared), and 4) 36% of injected cells remained by day 13 as solitary cancer cells, most of which were dormant (proliferation, 2%; apoptosis, 3%; in contrast to cells within macroscopic tumors: proliferation, 91%; apoptosis/necrosis, 6%). Thus, in this model, metastatic inefficiency is principally determined by two distinct aspects of cell growth after extravasation: failure of solitary cells to initiate growth and failure of early micrometastases to continue growth into macroscopic tumors.
在癌症转移过程中,只有一小部分从原发肿瘤释放出来的细胞能够成功形成远处病灶,但在这个过程的哪些步骤中细胞会丢失尚不确定。我们的目标是确定经门静脉注射到目标小鼠肝脏的B16F1黑色素瘤细胞的比例:1)存活并渗出;2)在第3天形成微转移灶(4至16个细胞);3)在第13天发展为肉眼可见的肿瘤;4)以单个休眠细胞的形式存在。通过体内视频显微镜、一种新型的细胞计数分析方法以及用于增殖(Ki-67)和凋亡(TUNEL)的免疫组化标记,我们发现:1)80%的注射细胞在肝脏微循环中存活并在第3天渗出;2)只有一小部分渗出细胞开始生长,每40个中有1个在第3天形成微转移灶;3)只有一小部分微转移灶继续生长,每100个中有1个在第13天发展为肉眼可见的肿瘤(实际上,大多数微转移灶消失了);4)到第13天,36%的注射细胞以单个癌细胞的形式存在,其中大多数处于休眠状态(增殖率为2%;凋亡率为3%;与肉眼可见肿瘤中的细胞相比:增殖率为91%;凋亡/坏死率为6%)。因此,在这个模型中,转移效率低下主要由渗出后细胞生长的两个不同方面决定:单个细胞无法启动生长以及早期微转移灶无法继续生长为肉眼可见的肿瘤。